APHIS Veterinary Biologic Patent Term Extension — How USDA Calculates Patent Restoration for Animal Vaccines and Biologics

Current Rule (2026)

Key Mechanics

A patent on an animal vaccine or veterinary biologic runs 20 years from the filing date — but a large chunk of that window gets consumed by mandatory federal review before the product can reach market. A company developing a new livestock vaccine may spend two to five years proving safety and potency to APHIS's Center for Veterinary Biologics before it receives a license (see APHIS Veterinary Biologics Program for the full licensing framework). That time is commercially dead: the patent clock is running but the product isn't selling.

The Drug Price Competition and Patent Term Restoration Act of 1984 — commonly called Hatch-Waxman — created a mechanism to claw some of that time back. Under 35 U.S.C. § 156, patent holders can apply to the U.S. Patent and Trademark Office (USPTO) for a term extension equal to the time spent in mandatory federal regulatory review. The statute caps the extension at five years and limits the total remaining patent life post-approval to 14 years — so a very short review period or a very late-stage filing may yield little or no extension.

Veterinary biologics fall under 21 U.S.C. §§ 151–159 (the Virus-Serum-Toxin Act), which requires federal licensing for any vaccine, bacterin, antiserum, or diagnostic kit sold in U.S. interstate commerce for use in animals. Because APHIS administers that licensing, APHIS is the designated regulatory agency for calculating what § 156 calls the "regulatory review period" — the window of mandatory government oversight that can be restored to the patent term.

9 CFR Part 124 is APHIS's procedural rulebook for handling these calculations. When a patent holder files a term extension application with USPTO, USPTO forwards it to APHIS. APHIS then has 30 days to determine whether the product was actually subject to APHIS review, calculate the length of that review in two phases, publish the determination in the Federal Register, and notify all parties. The two-phase structure under § 124.20 matters: Phase I runs from the date of the initial commercial marketing application to regulatory approval; Phase II runs from approval to first commercial marketing. APHIS sums both phases and sends the total to USPTO, which applies additional rules (37 CFR § 1.779) to compute the final extension.

Once APHIS publishes its determination, the clock starts on two challenge windows. Any interested person — typically a competitor hoping to limit the extension — can request a revision within 30 days of the Federal Register publication (§ 124.22). A separate, longer window of 180 days allows anyone to file a due diligence petition (§ 124.30), arguing that the patent holder was dilatory in pursuing APHIS approval. If the petition succeeds, the regulatory review period is trimmed by the period of inactivity, reducing the extension accordingly. The patent holder gets 20 days to respond (§ 124.31), and the Under Secretary for Marketing and Regulatory Programs must decide within 90 days (§ 124.32). If a party loses on due diligence, they can request an informal hearing within 60 days of that ruling (§§ 124.40–124.43); the Under Secretary issues a final administrative decision within 30 days of the hearing.

The due diligence standard under § 124.33 asks whether the applicant applied "the degree of attention, continuous directed effort, and timeliness as may reasonably be expected from, and are ordinarily exercised by, a person during a regulatory review period." In practice, this means gaps in submission history, periods of non-response to APHIS requests, or prolonged silence in the licensing docket can all become ammunition for competitors.

Key Provisions

How It Affects You

If you hold a patent on a veterinary biological product and you spent two or more years in APHIS's licensing pipeline before approval, calculate whether a term extension makes economic sense. File with USPTO — not APHIS — under 35 U.S.C. § 156. The extension cannot exceed five years, and your total patent life after first commercial marketing cannot exceed 14 years. For a blockbuster livestock vaccine with annual U.S. sales in the tens or hundreds of millions, even one additional year of exclusivity before generic competition arrives can be worth more than the entire R&D cost of the extension application. For a niche diagnostic product with modest revenues, the calculus looks different.

Documentation discipline during the APHIS licensing process is your best protection against a due diligence attack. APHIS builds the regulatory review period from its own records — but competitors build due diligence petitions from gaps in those same records. Maintain timestamped logs of every submission to APHIS, every response to agency requests, and every step of the licensing process. If APHIS asks for supplemental data, respond promptly and document the response date. A six-month gap in your licensing docket can cost you six months of patent extension if a competitor files a petition.

If you are a competitor whose product enters a market protected by a veterinary biologic patent, watch the Federal Register for APHIS regulatory review period determinations. You have 30 days to request a revision and 180 days to file a due diligence petition. Review the patent holder's APHIS licensing history — obtainable via FOIA — for periods of inactivity. A successful petition that trims even one year from the extension can meaningfully change your generic or biosimilar launch timeline and market opportunity. For the parallel competitive dynamics in human biologic drugs, see Biosimilars & the BPCIA.

If you are an animal health company evaluating pipeline investments, factor patent term extension value into your return-on-investment models. Products with long APHIS review periods (common for novel vaccine platforms or complex biologics) may generate the most extension, but only if the applicant maintains a clean diligence record. Build that into your product development SOPs from day one, not after you file the patent extension application. The facility and product licensing requirements that generate the regulatory review period are detailed in APHIS Facility Requirements for Licensed Veterinary Biologic Establishments.

Legal Authority

Patent term restoration framework (see also Patent Law):

• 35 U.S.C. § 156 — Extension of patent term. A patent covering a product, a method of using a product, or a method of manufacturing a product may receive additional term beyond its normal 20-year life if the product underwent mandatory federal regulatory review before it could be commercially marketed. Key limits: the extension cannot exceed 5 years; the total remaining patent life after first commercial marketing (including the extension) cannot exceed 14 years; only one patent may be extended per regulatory review period; interim extensions of up to one year may be granted when a review might outlast the patent, with up to four additional interim extensions available. The patent holder must apply within 60 days of first receiving marketing authorization. APHIS is the designated regulatory agency for veterinary biological products; FDA handles human drugs and medical devices.
• 37 CFR § 1.779 — USPTO regulations governing the overall patent term extension calculation framework; APHIS's regulatory review period determination feeds directly into this framework.

Virus-Serum-Toxin Act (the regulatory review process being measured):

• 21 U.S.C. § 151 — Prohibits preparation, sale, trade, or shipment of worthless, contaminated, dangerous, or harmful veterinary biological products; requires production at licensed establishments operating under USDA rules. This is the core prohibition that makes APHIS licensing mandatory.
• 21 U.S.C. § 152 — Regulates and prohibits importation of veterinary biological products without an APHIS permit (or, for Canadian products, an accepted Canadian certificate). Imports are subject to the same licensing framework.
• 21 U.S.C. § 153 — Authorizes APHIS inspection of imported veterinary biological products; requires denial of entry and destruction or return of products found worthless, contaminated, dangerous, or harmful at the importer's expense.
• 21 U.S.C. § 154 — Authorizes the Secretary of Agriculture to promulgate rules governing the preparation and sale of veterinary biological products, and to issue, suspend, or cancel establishment licenses. This is the core licensing authority whose exercise creates the regulatory review period.
• 21 U.S.C. § 155 — Governs permits for importation of veterinary biological products.
• 21 U.S.C. § 156 — Requires that licenses for veterinary biological product establishments permit federal inspection of the facility, products, and manufacturing process; authorizes suspension or cancellation of licenses used to facilitate harmful or contaminated products after a hearing.
• 21 U.S.C. § 157 — Authorizes USDA inspectors to inspect establishments day or night.
• 21 U.S.C. § 158 — Criminal penalties for VSTA violations: up to a $1,000 fine and/or up to one year imprisonment.
• 21 U.S.C. § 159 — Enforcement procedures and Congressional findings; establishes the interstate commerce basis for federal regulation of veterinary biologics.

Recent Rulemakings

The 9 CFR Part 124 procedural framework has been stable since its initial promulgation. No major Federal Register amendments have altered the calculation methodology, the 30-day determination deadline, or the due diligence petition process. The regulatory review period rules track the underlying Hatch-Waxman statute, which Congress has not amended in material ways affecting veterinary biologics.

APHIS regulatory review period determinations for individual products appear in the Federal Register as they are issued. These are product-specific calculations, not rulemaking, so they do not modify Part 124 itself — but they establish the agency's working interpretation of the two-phase calculation in practice.

Pending Legislation

No bills in the 119th Congress (2025–2026) directly target APHIS's veterinary biologic patent term extension procedures under 9 CFR Part 124. The broader patent-term and biologic patent landscape has seen related activity:

• HR 1492 (119th Congress) — Would equalize the drug price negotiation period between small-molecule drugs (7 years) and biologics (11 years) under the IRA's Drug Price Negotiation Program. While focused on human drugs, this reflects ongoing congressional attention to the asymmetric IP treatment of biologic versus small-molecule products — a debate that occasionally surfaces in the veterinary biologic context as well.
• HR 4850 — Biologic Patent Transparency Act (116th Congress, Rep. Spanberger [D-VA-7]): Would have required biologic manufacturers to disclose patent portfolios covering licensed biologic products, increasing transparency about which patents extend market exclusivity. Referred to the Subcommittee on Courts, Intellectual Property, and the Internet; did not advance.
• HR 7035 — Biologics Market Transparency Act of 2022 (117th Congress, Rep. Manning [D-NC-6]): Would have required FDA to publish a list of patents covering approved biologic products, analogous to the Orange Book for small-molecule drugs. Referred to the Subcommittee on Health; did not advance.
• HR 8877 — Biologics Competition Act of 2022 (117th Congress, Rep. Miller-Meeks [R-IA-2]): Would have incentivized biosimilar entry by modifying biologic exclusivity periods. Referred to committee; did not advance.

None of these bills modify APHIS's procedures under 9 CFR Part 124 directly, but the broader political focus on biologic patent exclusivity could eventually produce proposals affecting how veterinary biologics are treated in the Hatch-Waxman framework.

Recent Developments

April 2026 — FDA Publishes Analogous Regulatory Review Period Determination for UNLOXCYT (91 FR 20467). While APHIS handles veterinary biologics, FDA runs a parallel process for human biologics (see FDA Drug Approval). In April 2026, FDA published its regulatory review period determination for UNLOXCYT, a human biological product, in the Federal Register (Document 2026-07422). The determination gives interested persons until June 15, 2026 to challenge the dates and until October 13, 2026 to file a due diligence petition — the same dual-challenge structure that applies to APHIS veterinary biologic determinations under 9 CFR Part 124. Watching FDA's parallel process is instructive: it illustrates how these determinations look in practice and how the 30-day/180-day deadlines operate.

2025–2026 — APHIS Leadership Transitions. Associate Administrator Michelle Wenberg retired in 2025 after 38 years of federal service, including a key role in regulatory development affecting APHIS programs. Matthew Rhoads was appointed Deputy Administrator for Plant Protection and Quarantine, and Hallie Zimmers was appointed Deputy Administrator for Emergency and Regulatory Compliance Services. Leadership transitions at APHIS do not affect the legal framework under 9 CFR Part 124, but they signal organizational changes at the agency responsible for administering the regulatory review period process.

April 2026 — Pseudorabies Confirmed in Commercial Swine (APHIS Context). APHIS confirmed the first pseudorabies detection in commercial swine since 2004 eradication, affecting herds in Iowa and Texas. This has no direct impact on 9 CFR Part 124 patent term procedures, but it highlights the active veterinary disease surveillance context in which APHIS's Center for Veterinary Biologics operates — the same center responsible for administering licensing reviews whose duration determines patent extension eligibility.